Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2).

Abstract

BACKGROUND AND OBJECTIVES:

Photodynamic therapy (PDT) using a photoreactive purpurin, tin ethyl etiopurpurin (SnET2, Purlytin, Miravant Medical Technologies, Santa Barbara, CA), was investigated as a treatment for cutaneous metastatic disease that had failed other treatment options.

STUDY DESIGN/MATERIALS AND METHODS:

Three patients with biopsy-proven metastatic adenocarcinoma of the skin were treated with a single dose of the study drug. Twenty-four hours later, the patients were exposed to a laser light at 664 nm in multiple light fields. Patients were followed for 6 months for safety, efficacy, recurrence, and palliative response.

RESULTS:

After PDT with SnET2, complete response was observed in all 13 treated lesions in three patients, with no evidence of recurrence at any treated site at the 6-month follow-up. Two patients subsequently died of distant metastatic disease. One patient with local chest wall recurrence after mastectomy was disease-free 24 months after PDT.

CONCLUSIONS:

PDT with SnET2 could be an effective treatment in locally advanced metastatic carcinoma of the skin.

• Authors: M J Kaplan, R G Somers, R H Greenberg, J Ackler
• Journal: Journal of surgical oncology (J Surg Oncol) Vol. 67 Issue 2 Pg. 121-5 (Feb 1998) ISSN: 0022-4790 [Print] United States
• PMID: 9486784 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Porphyrins
• Radiation-Sensitizing Agents
• tin etiopurpurin

Topics

• Adenocarcinoma (drug therapy, pathology, secondary)
• Female
• Humans
• Middle Aged
• Photochemotherapy
• Porphyrins (therapeutic use)
• Radiation-Sensitizing Agents (therapeutic use)
• Skin Neoplasms (drug therapy, pathology, secondary)
• Submandibular Gland Neoplasms (pathology)